LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial

334-OR: Pemvidutide (ALT-801) , a Balanced (1:1) GLP-1/Glucagon Dual Receptor Agonist, Induces Rapid and Marked Weight Loss without the Need for Dose Titration in People with Overweight/Obesity

(2022) SAMUEL KLEIN et al.   DIABETES

Efficacy and safety of cotadutide, a dual glucagon‐like peptide‐1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease

(2022) Victoria E. R. Parker et al.   DIABETES OBESITY & METABOLISM

Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial

(2022) Tim Heise et al.   Lancet Diabetes & Endocrinology

Is Glucagon Receptor Activation the Thermogenic Solution for Treating Obesity?

(2022) Ellen Conceição-Furber et al.   Frontiers in Endocrinology

333-OR: Oxyntomodulin Analog LY3305677 (LY) Improves Glycemic Control and Weight Loss in Healthy Volunteers and Subjects with Type 2 Diabetes (T2D)

(2022) CHARLES BENSON et al.   DIABETES

Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective

(2022) Christophe De Block et al.   DIABETES OBESITY & METABOLISM

Tirzepatide Once Weekly for the Treatment of Obesity

(2022) Ania M. Jastreboff et al.   NEW ENGLAND JOURNAL OF MEDICINE

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

(2022) Tamer Coskun et al.   Cell Metabolism

Once-Weekly Semaglutide in Adults with Overweight or Obesity

(2021) John P.H. Wilding et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study

(2021) Rajaa Nahra et al.   DIABETES CARE

Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial

(2021) Juan P Frías et al.   Lancet Diabetes & Endocrinology

Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist

(2021) Martin Bossart et al.   Cell Metabolism

Glucagon Receptor Signaling and Lipid Metabolism

(2019) Katrine D. Galsgaard et al.   Frontiers in Physiology

MEDI0382, a GLP-1-glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomised, phase 1 study

(2018) Philip D. Ambery et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Incretin hormones: Their role in health and disease

(2018) Michael A. Nauck et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

(2018) Juan Pablo Frias et al.   LANCET

The New Biology and Pharmacology of Glucagon

(2017) T. D. Müller et al.   PHYSIOLOGICAL REVIEWS

A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes

(2015) Michael A. Nauck et al.   DIABETES CARE

Glucagon increases energy expenditure independently of brown adipose tissue activation in humans

(2015) V. Salem et al.   DIABETES OBESITY & METABOLISM

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents

(2014) Brian Finan et al.   NATURE MEDICINE

Glucose-Dependent Insulinotropic Polypeptide: A Bifunctional Glucose-Dependent Regulator of Glucagon and Insulin Secretion in Humans

(2011) M. Christensen et al.   DIABETES

LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects

(2011) P. Barrington et al.   DIABETES OBESITY & METABOLISM

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

(2009) Jonathan W Day et al.   Nature Chemical Biology